Compare FINV & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINV | VERA |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | 2021 |
| Metric | FINV | VERA |
|---|---|---|
| Price | $5.04 | $33.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $11.55 | ★ $61.71 |
| AVG Volume (30 Days) | ★ 1.7M | 1.7M |
| Earning Date | 11-19-2025 | 11-05-2025 |
| Dividend Yield | ★ 5.72% | N/A |
| EPS Growth | ★ 27.76 | N/A |
| EPS | ★ 1.50 | N/A |
| Revenue | ★ $1,969,555,571.00 | N/A |
| Revenue This Year | $11.56 | N/A |
| Revenue Next Year | $8.06 | N/A |
| P/E Ratio | $3.33 | ★ N/A |
| Revenue Growth | ★ 8.81 | N/A |
| 52 Week Low | $4.70 | $18.53 |
| 52 Week High | $11.08 | $51.27 |
| Indicator | FINV | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 33.21 | 66.36 |
| Support Level | $4.70 | $27.19 |
| Resistance Level | $5.29 | $29.90 |
| Average True Range (ATR) | 0.25 | 2.15 |
| MACD | -0.04 | 0.57 |
| Stochastic Oscillator | 19.82 | 93.18 |
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.